APA (7th ed.) Citation

Dawwas, G. K., Cuker, A., Barnes, G. D., Lewis, J. D., & Hennessy, S. (2022). Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study. Annals of Internal Medicine, 175(11), 1506. https://doi.org/10.7326/M22-0318

Chicago Style (17th ed.) Citation

Dawwas, Ghadeer K., Adam Cuker, Geoffrey D. Barnes, James D. Lewis, and Sean Hennessy. "Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study." Annals of Internal Medicine 175, no. 11 (2022): 1506. https://doi.org/10.7326/M22-0318.

MLA (9th ed.) Citation

Dawwas, Ghadeer K., et al. "Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study." Annals of Internal Medicine, vol. 175, no. 11, 2022, p. 1506, https://doi.org/10.7326/M22-0318.